Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663

Watchlist Manager
Bharat Immunologicals and Biologicals Corporation Ltd Logo
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Watchlist
Price: 23.21 INR -1.36%
Market Cap: 1B INR
Have any thoughts about
Bharat Immunologicals and Biologicals Corporation Ltd?
Write Note

Bharat Immunologicals and Biologicals Corporation Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bharat Immunologicals and Biologicals Corporation Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Cost of Revenue
-â‚ą218.1m
CAGR 3-Years
37%
CAGR 5-Years
8%
CAGR 10-Years
17%
Transgene Biotek Ltd
BSE:526139
Cost of Revenue
-â‚ą4k
CAGR 3-Years
81%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Cost of Revenue
-â‚ą2.1m
CAGR 3-Years
-129%
CAGR 5-Years
15%
CAGR 10-Years
31%
Hester Biosciences Ltd
NSE:HESTERBIO
Cost of Revenue
-â‚ą901.3m
CAGR 3-Years
-11%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Cost of Revenue
-â‚ą49.3B
CAGR 3-Years
-28%
CAGR 5-Years
-21%
CAGR 10-Years
-15%
Panacea Biotec Ltd
NSE:PANACEABIO
Cost of Revenue
-â‚ą2B
CAGR 3-Years
7%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
No Stocks Found

Bharat Immunologicals and Biologicals Corporation Ltd
Glance View

Market Cap
1B INR
Industry
Biotechnology

Bharat Immunologicals & Biologicals Corp. Ltd. is a biotechnology company, which engages in the manufacture and market of pharmaceutical products. The company is headquartered in Bulandshahr, Uttar Pradesh. The firm is primarily engaged in the manufacture of Oral polio Vaccine, Zinc Tablets, Diarrhea management Kit and BIB Sweet Tablets. The company is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The firm is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). The company is also diversified into Plasma-derived medicines and Oral Cholera vaccines. The firm's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.

BIBCL Intrinsic Value
5.26 INR
Overvaluation 77%
Intrinsic Value
Price

See Also

What is Bharat Immunologicals and Biologicals Corporation Ltd's Cost of Revenue?
Cost of Revenue
-218.1m INR

Based on the financial report for Sep 30, 2023, Bharat Immunologicals and Biologicals Corporation Ltd's Cost of Revenue amounts to -218.1m INR.

What is Bharat Immunologicals and Biologicals Corporation Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
17%

Over the last year, the Cost of Revenue growth was 72%. The average annual Cost of Revenue growth rates for Bharat Immunologicals and Biologicals Corporation Ltd have been 37% over the past three years , 8% over the past five years , and 17% over the past ten years .

Back to Top